Related Experiment Video
Updated: Jul 7, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Cyclic Thrombocytopenia Complicated by Thrombosis and Successfully Treated With Rituximab: A Diagnostic and
Jandir Mendonça Nicacio1,2, Lucyo Flávio Bezerra Diniz2, Andre Luis Magalhães Fernandes3
1Department of Medicine Federal University of São Francisco Valley.
Cyclic thrombocytopenia (CTP) is a rare hematologic disorder characterized by fluctuating platelet counts and is often misdiagnosed as immune thrombocytopenia. We present the case of a 51-year-old woman with a history of severe thrombocytopenia and mucocutane-ous bleeding since 2012, initially treated as immune thrombocytopenia with corticoster-oids, splenectomy, and azathioprine, without sustained response. Over time, she devel-oped pronounced cyclic fluctuations in platelet counts (<10,000/mm³ to >150,000/mm³) every 21 days. Treatment with eltrombopag resulted in deep venous thrombosis and a major pulmonary bleeding episode associated with anticoagulation. After secondary causes and bone marrow disorders were excluded, cyclic thrombocytopenia was diag-nosed. Rituximab (375 mg/m² weekly for four weeks) led to a significant reduction in platelet oscillations, with no further significant bleeding. This case highlights the diagnos-tic challenges of CTP, underscores the thrombotic risks of thrombopoietin receptor agonists, and supports rituximab as a potential treatment for refractory cases with high thrombo-hemorrhagic risk.
Cyclic thrombocytopenia (CTP) is a rare hematologic disorder characterized by fluctuating platelet counts and is often misdiagnosed as immune thrombocytopenia. We present the case of a 51-year-old woman with a history of severe thrombocytopenia and mucocutane-ous bleeding since 2012, initially treated as immune thrombocytopenia with corticoster-oids, splenectomy, and azathioprine, without sustained response. Over time, she devel-oped pronounced cyclic fluctuations in platelet counts (<10,000/mm³ to >150,000/mm³) every 21 days. Treatment with eltrombopag resulted in deep venous thrombosis and a major pulmonary bleeding episode associated with anticoagulation. After secondary causes and bone marrow disorders were excluded, cyclic thrombocytopenia was diag-nosed. Rituximab (375 mg/m² weekly for four weeks) led to a significant reduction in platelet oscillations, with no further significant bleeding. This case highlights the diagnos-tic challenges of CTP, underscores the thrombotic risks of thrombopoietin receptor agonists, and supports rituximab as a potential treatment for refractory cases with high thrombo-hemorrhagic risk.